Pharmaceutical

Filter

Current filters:

None

Popular Filters

1 to 25 of 7006 results

FDA backs added use for UCB’s Vimpat

01-09-2014

Belgium’s largest drugmaker UCB said today that the US Food and Drug Administration has approved a…

NeurologicalPharmaceuticalRegulationUCBUSAVimpat

Numbers of clinical trials in Denmark have stabilized

Numbers of clinical trials in Denmark have stabilized

01-09-2014

New figures from Danish pharmaceutical industry trade groups Lif and Dansk Biotek reveal that 296 clinical…

DenmarkPharmaceuticalPoliticsResearch

Thrombogenics gets Spanish reimbursement approval for Jetrea

Thrombogenics gets Spanish reimbursement approval for Jetrea

01-09-2014

Ophthalmic specialist ThromboGenics has received reimbursement in Spain from the Spanish Ministry of…

AlconJetreaNon-steroidal anti-inflammatory drugsOphthalmicsPharmaceuticalRegulationSpainThromboGenics

Vifor reports positive results from Ferinject study for chronic heart failure

Vifor reports positive results from Ferinject study for chronic heart failure

01-09-2014

Switzerland-based iron specialist Vifor Pharma says its Ferinject (ferric carboxymaltose) has met its…

Cardio-vascularChronic heart failureFerinjectPharmaceuticalRegulationSwitzerlandVifor Pharma

Ablynx out-licenses ozoralizumab for Greater China to Eddingpharm

Ablynx out-licenses ozoralizumab for Greater China to Eddingpharm

01-09-2014

Belgian drug developer Ablynx has expanded its relationship with China’s Eddingpharm, by granting the…

AblynxAnti-Arthritics/RheumaticsChinaEddingpharmLicensingMarkets & MarketingozoralizumabPharmaceutical

Chugai and Roche amend business arrangements on out-licensing

Chugai and Roche amend business arrangements on out-licensing

31-08-2014

Japanese drugmaker Chugai has amended the business arrangements with its majority (62%) share-owner Swiss…

Asia-PacificChugai PharmaceuticalEuropeLicensingPharmaceuticalRoche

Novartis' investigational heart failure drug LCZ696 shows striking efficacy

Novartis' investigational heart failure drug LCZ696 shows striking efficacy

31-08-2014

Swiss drug major Novartis on Saturday presented striking new data for its LZC696 heart drug at the European…

Cardio-vascularLCZ696NovartisPharmaceuticalRegulationResearch

Takeda and Lilly fail to overturn $9 billion award for hiding cancer risk of Actos

Takeda and Lilly fail to overturn $9 billion award for hiding cancer risk of Actos

31-08-2014

Japan’s largest drugmaker Takeda Pharmaceutical and US pharma major Eli Lilly have failed in their…

ActosDiabetesEli LillyFinancialLegalPharmaceuticalTakeda PharmaceuticalUSA

New studies planned to further expand indications for Xarelto

New studies planned to further expand indications for Xarelto

29-08-2014

German pharma major Bayer and partner Janssen Research & Development, a unit of US health care giant…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalResearchXarelto

FTC puts conditions on acquisition of Insight Pharma by Prestige Brands

29-08-2014

US firm Prestige Brands Holdings, the maker of Dramamine (dimenhydrinate), has agreed to divest assets…

Insight PharmaceuticalsMergers & AcquisitionsPharmaceuticalPrestige BrandsRegulationUSA

Ipsen posts strong earnings growth for first-half 2014

Ipsen posts strong earnings growth for first-half 2014

29-08-2014

French drugmaker Ipsen has reported first half 2014 sales of 638.7 million euros ($845.1 million), up…

FinancialIpsenPharmaceutical

FDA approves Elelyso for pediatric use in Gaucher disease

FDA approves Elelyso for pediatric use in Gaucher disease

29-08-2014

The US Food and Drug Administration has approved US pharma giant Pfizer’s Elelyso (taliglucerase alfa)…

ElelysoPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesRegulationUSA

Colorectal cancer market will remain steady at $7.7 billion by 2023; report

29-08-2014

The market for colorectal cancer (CRC) therapies will remain constant, at around $7.7 billion by 2023…

EuropeJapanMarkets & MarketingOncologyPharmaceuticalUSA

Tau Therapeutics and Xdynia merge to form Cavion

29-08-2014

Privately-held US drugmakers Tau Therapeutics and Xdynia announced today that they have merged; the surviving…

CavionMergers & AcquisitionsNeurologicalOncologyPharmaceuticalTau TherapeuticsXdynia

Curious resilience of the $50,000-per-QALY threshold

28-08-2014

For more than two decades, the ratio of $50,000 per quality-adjusted life-year (QALY) gained by using…

HealthcarePharmaceuticalPricingRegulationUSA

Daiichi Sankyo links with Kaketsuken for Bimmugen sales

28-08-2014

Japanese drug major Daiichi Sankyo has signed a cooperative sales agreement with The Chemo-Sero-Therapeutic…

Anti-viralsBimmugenDaiichi SankyoJapanKaketsukenLicensingMarkets & MarketingPharmaceuticalVaccines

Jez Moulding named head of Sanofi's North American business

Jez Moulding named head of Sanofi's North American business

28-08-2014

French drug major Sanofi has replaced its North American chief Anne Whitaker with Jez Moulding, who will…

BoardroomNorth AmericaPharmaceuticalSanofi

Cardiovascular disease has already cost six EU countries over $100 billion in 2014 alone

Cardiovascular disease has already cost six EU countries over $100 billion in 2014 alone

28-08-2014

Research by Anglo-Swedish drug major AstraZeneca into the cost burden of cardiovascular disease has shown…

AstraZenecaCardio-vascularEconomy of the European UnionEuropePharmaceuticalResearch

1 to 25 of 7006 results

Back to top